Physician profile
Nicolas P Xydas
NPI 1922034669
$19,071.21
in general payments reported to CMS, 2019-2025
19 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $118 · 2021: $112 · 2022: $77.73 · 2023: $368 · 2024: $7,600 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $803 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,600.00 |
| Food and Beverage | $803.42 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $17,600.00 | 2024-2025 | Bovine Collagen |
| Astellas Pharma US INC | $465.59 | 2022-2025 | Veozah, Myrbetriq |
| Shield Therapeutics INC | $217.11 | 2022-2024 | Accrufer |
| Abbvie INC. | $212.56 | 2019-2021 | |
| Hologic Sales and Service, LLC | $168.78 | 2019-2023 | Aptima |
| Ethicon US, LLC | $86.55 | 2025 | Echelon Flex, Vistaseal, Evarrest |
| Biogen, INC. | $56.41 | 2025 | Zurzuvae |
| Mission Pharmacal Company | $52.80 | 2019-2023 | Citranatal |
| Mayne Pharma Commercial LLC | $41.94 | 2022-2025 | |
| Pfizer INC. | $29.11 | 2025 | |
| Innovation Technologies INC | $20.68 | 2025 | Irrisept |
| Bayer Healthcare Pharmaceuticals INC. | $17.68 | 2019 | |
| Optumhealth Care Solutions, LLC | $17.43 | 2024 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Galderma Laboratories, L.P. | $16.77 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $16.55 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $15.97 | 2021 | |
| Lupin INC. | $12.07 | 2019 | |
| Merck Sharp & Dohme LLC | $11.62 | 2021 | |
| Therapeuticsmd, INC. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicolas Xydas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.